We are live on
!
Find out more
AC
Armistice Capital Portfolio holdings
AUM
$5.62B
1-Year Est. Return
36.06%
This Fund
S&P 500
This Quarter
Est. Return
+15.6%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$8.4B
AUM Growth
+$1.66B
(+25%)
Cap. Flow
+$1.33B
Cap. Flow
% of AUM
15.85%
Top 10 Holdings %
Top 10 Hldgs %
61.33%
Holding
510
New
182
Increased
113
Reduced
52
Closed
146
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Agios Pharmaceuticals
AGIO
|
+$79.7M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$74.4M |
| 3 |
Kenvue
KVUE
|
+$65.3M |
| 4 |
e.l.f. Beauty
ELF
|
+$51.7M |
| 5 |
GSK
GSK
|
+$46.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Travere Therapeutics
TVTX
|
+$96.3M |
| 2 |
EXAS
Exact Sciences
EXAS
|
+$56.4M |
| 3 |
PTC Therapeutics
PTCT
|
+$34.5M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$28M |
| 5 |
MongoDB
MDB
|
+$23M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 32.56% |
| 2 | Technology | 5.44% |
| 3 | Consumer Discretionary | 5.13% |
| 4 | Consumer Staples | 2.69% |
| 5 | Communication Services | 1.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Core Scientific
CORZ
$6.8B
| $285K | ﹤0.01% |
+19,589
| New | +$342K |
|
302
Frontline
FRO
$8.85B
| $285K | ﹤0.01% |
+13,069
| New | +$305K |
|
303
Robinhood
HOOD
$83.8B
| $283K | ﹤0.01% |
2,506
+804
| +47% | +$105K |
|
|
BLSH
304
Bullish
BLSH
$3.55B
| $281K | ﹤0.01% |
+7,419
| New | +$361K |
|
|
NGD
305
DELISTED
New Gold Inc
NGD
| $279K | ﹤0.01% |
+32,070
| New | +$242K |
|
306
Entergy
ETR
$50.1B
| $278K | ﹤0.01% |
+3,009
| New | +$285K |
|
307
Blackstone
BX
$110B
| $276K | ﹤0.01% |
+1,789
| New | +$272K |
|
308
Charter Communications
CHTR
$18.2B
| $273K | ﹤0.01% |
+1,309
| New | +$294K |
|
309
California Resources
CRC
$4.64B
| $272K | ﹤0.01% |
+6,086
| New | +$289K |
|
|
DFSC
310
DEFSEC Technologies
DFSC
$3.36M
| $269K | ﹤0.01% |
+158,036
| New | +$549K |
|
|
MIAX
311
Miami International Holdings
MIAX
$4.34B
| $264K | ﹤0.01% |
+5,947
| New | +$265K |
|
312
JPMorgan Chase
JPM
$951B
| $264K | ﹤0.01% |
819
-69
| -8% | -$21.4K |
|
313
Assured Guaranty
AGO
$3.42B
| $263K | ﹤0.01% |
2,923
+53
| +2% | +$4.57K |
|
314
Coca-Cola
KO
$375B
| $262K | ﹤0.01% |
+3,754
| New | +$262K |
|
315
Equifax
EFX
$21.3B
| $261K | ﹤0.01% |
+1,202
| New | +$263K |
|
316
Sportradar
SRAD
$3.83B
| $260K | ﹤0.01% |
+10,940
| New | +$263K |
|
317
Curtiss-Wright
CW
$25.6B
| $259K | ﹤0.01% |
+469
| New | +$262K |
|
318
M&T Bank
MTB
$36.2B
| $257K | ﹤0.01% |
+1,277
| New | +$244K |
|
319
GE Aerospace
GE
$385B
| $256K | ﹤0.01% |
832
-9,273
| -92% | -$2.79M |
|
320
Comcast
CMCSA
$90.3B
| $251K | ﹤0.01% |
+8,946
| New | +$255K |
|
321
D.R. Horton
DHI
$42.1B
| $240K | ﹤0.01% |
+1,664
| New | +$253K |
|
322
Open Text
OTEX
$5.98B
| $239K | ﹤0.01% |
+7,335
| New | +$261K |
|
|
SNDK
323
Sandisk
SNDK
$180B
| $237K | ﹤0.01% |
+997
| New | +$200K |
|
324
Cheniere Energy
LNG
$54.2B
| $236K | ﹤0.01% |
+1,213
| New | +$255K |
|
|
EXE
325
Expand Energy Corp
EXE
$21.6B
| $235K | ﹤0.01% |
+2,126
| New | +$236K |
|
Similar funds
CRC
RMDI
F
EW
O
DSC
ACM
PI
Armistice Capital's Q4 2025 Portfolio in Review
As of Q4 2025, Armistice Capital held 510 positions worth $8.4B, up 25% from $6.74B the previous quarter. Its ten largest holdings account for 61% of the portfolio.
Armistice Capital deployed $1.33B of net new capital in Q4 2025, opening 182 new positions and adding to 113 existing holdings. Its largest new stake was Kenvue: 3,992,196 shares worth $68.9M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 32% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Travere Therapeutics, an estimated $96.3M trimmed.
- Armistice Capital's largest Q4 2025 buy was Kenvue: 3,992,196 shares worth $68.9M.
- Armistice Capital added most to Agios Pharmaceuticals in Q4 2025, an estimated $79.7M increase.
- Armistice Capital's biggest Q4 2025 reduction was Travere Therapeutics, cutting an estimated $96.3M.
- Armistice Capital fully exited Exact Sciences in Q4 2025, selling an estimated $56.4M.
- Armistice Capital's ten largest holdings make up 61% of its $8.4B portfolio in Q4 2025.
- Armistice Capital opened 182 new positions and closed 146 in Q4 2025.
- Armistice Capital's portfolio value rose 25% quarter-over-quarter to $8.4B.
Based on Armistice Capital's 13F filing for Q4 2025, filed 17 Feb 2026.